Business Wire

AFC Energy launches Hyamtec Limited (“Hyamtec”) to unlock the global hydrogen value chain

Share

Delivering next generation Ammonia Cracking Technology

Hyamtec, the UK’s newest hydrogen company, has been launched by AFC Energy plc to deliver next generation modular ammonia cracking technology.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240918101995/en/

Aerial view of ammonia cracker site (Photo: Business Wire)

Hyamtec can make on-site, on-demand hydrogen at just 10% of the cost of truck delivered hydrogen and will prioritise natural gas displacement in the hard to abate heavy industrial sectors which account for 50% of global carbon emissions.

Hyamtec will target areas which represent a £40 billion market in the UK alone:

  • Hydrogen rich combustible fuel gas for the decarbonisation of industrial heat generation;
  • Ammonia conversion of large combustion engines for power generation, marine and mining; and
  • Modular purified hydrogen production for fuel cells and transportation.

Hydrogen is the solution for decarbonisation of heavy industry and green hydrogen plants will dominate new capacity and by 2030, up to 20% of hydrogen produced globally will be green. This production will be located where the renewable energy required is abundant plentiful and cheap; however, hydrogen is difficult to store and transport, and it will take decades to install hydrogen pipelines. To transport the hydrogen to where it will be used, typically thousands of miles away, will require it to be moved as ammonia and then converted back to hydrogen.

Hyamtec’s technology can achieve this on-site at the lowest cost and highest efficiency to provide a solution to unlock industrial decarbonisation at scale. Hyamtec crackers have proven their ability to integrate with ammonia combustion engines (as a pilot fuel) and to deliver ISO Grade hydrogen for use in fuel cell applications.

Dr. Mike Rendall, Managing Director of Hyamtec Limited, said:

“Hyamtec is focused on fast tracking the decarbonisation of industry through ammonia and our ammonia cracking technologies. With over £40bn spent per annum on natural gas by industrial users in the UK alone, the global opportunity to displace fossil fuels in industry with ammonia is immense.

“The global journey to net zero will require the rapid development of hydrogen-based technologies. We look forward to partnering with industry to support the rapid decarbonisation of the world’s hardest to abate sectors and to announcing Hyamtec’s first commercial deals soon.”

Find out more at www.hyamtec.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20240918101995/en/

Contacts

Hyamtec Ltd

Hyamtec Ltd
Mike Rendall, Managing Director
+44 (0) 14 8327 6726
FTI Consulting – PR Advisors
afcenergy@fticonsulting.com

afcenergy@fticonsulting.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye